In the future research, the main issues need to be paid attention to include whether a relational treatment combination can completely block or partially inhibit mTOR pathway, and whether subtype specific or pan-PI3K inhibition can provide additional benefits for BC patients. This evidence concerns the gene MTOR and breast cancer.